Methods for treating an inflammatory disease of the bowel
View Patent ↗The invention relates to an assay to select a candidate drug for the treatment of inflammatory disease due to cytokine production. The assay comprises: a) exposing said candidate drug to intestinal cells; and b) analysing the effect of the said candidate drug selected from the group consisting of the variation of nuclear export or import of transcription factors from the NF-κB family the disruption of transcriptional activity of transcription factors from the NF-κB family, the differential histone acetylation of p65 (RelA); the variation of the amount of PPARγ/RelA complexes in the cytosol of the cells; and a combination thereof. The invention further relates to methods for the treatment of inflammatory cytokine production associated diseases and to the use of a therapeutically effective dose of Bacteroides thetaiotaomicron or a component thereof.
1. A method of treating inflammatory response of intestinal cells in a mammal afflicted with an inflammatory disease of the bowel, said inflammatory response being caused by NF-κB-induced inflammatory cytokines, said method comprising the step of administering to the subject a composition comprising as the only bacterial anti-inflammatory active ingredient a therapeutically effective dose of Bacteroides thetaiotaomicron.
2. The method of claim 1 , wherein said Bacteroides thetaiotaomicron are administered live to the subject by means of a foodstuff or suppository.
3. The method of claim 1 , wherein said inflammatory disease of the bowel is Crohn's disease.
4. The method of claim 1 , wherein the therapeutically effective dose of Bacteroides thetaiotaomicron is delivered orally.
5. The method of claim 1 , wherein transcriptional activity of NF-κB is altered in the subject by enhanced nuclear export of the NF-κB.
6. The method of claim 1 , wherein an amount of PPARγ/RelA complexes in the cell cytosol of the subject is increased.
7. The method of claim 1 , wherein said inflammatory response is determined through measurement of the levels of one or more cytokines selected from the group consisting of TNF-α, IL-8, MIP-2α and Cox-2.